Online inquiry

IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14627MR)

This product GTTS-WQ14627MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets DLL3 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_016941.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10683
UniProt ID Q9NYJ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14627MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8626MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HuM195
GTTS-WQ2618MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 557
GTTS-WQ12081MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MOR-00208
GTTS-WQ5011MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA c4G7-N
GTTS-WQ12189MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MORAb-022
GTTS-WQ12847MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ONC-005
GTTS-WQ15595MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA VAL-1221
GTTS-WQ261MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 17-1A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW